DEMANT Demant A/S

Demant A/S: Ledende medarbejderes transaktioner

Demant A/S: Ledende medarbejderes transaktioner

Selskabsmeddelelse nr. 2020-092. juli 2020

Ledende medarbejderes og disses nærtståendes transaktioner med Demant A/S-aktier

Indberetning i henhold til markedsmisbrugsforordningens artikel 19, stk. 1, litra a, af ledende medarbejderes og disses nærtståendes transaktioner med Demant A/S-aktier:

1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne
a)NavnAnja Madsen
2.Årsag til indberetningen
a)Stilling/titelMedlem af bestyrelsen
b)Første indberetning/ændringFørste indberetning
3)Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auk-

tionsplatformen, auktionsholderen eller den auktionstilsynsførende
a)NavnDemant A/S
b)LEI-kode213800RM6L9LN78BVA56
4.Nærmere oplysninger om transaktionen/transaktionerne: Gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktioner
a)Beskrivelse af det finansielle

instrument, instrumenttypen



 



Identifikationskode
Aktier



 



 



DK0060738599
b)Transaktionens artKøb
c)Pris(er) og mængde(r)Pris  Mængde

DKK 176,20  751 stk.

DKK 176,00  100 stk.
d)Aggregerede oplysninger:

- Aggregeret mængde

- Pris
 



851 stk.

DKK 176,17
e)Dato for transaktionen29. juni 2020
f)Sted for transaktionenNasdaq Copenhagen A/S

* * * * * * *

Yderligere information:

Christian Lange, Investor Relations Officer

Trine Kromann-Mikkelsen, VP Corporate Communication & Relations

Telefon

 

 

Vedhæftet fil

EN
02/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Demant A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK400.00) - 2024 likely to be back-end loaded

We forecast Q1 organic revenue growth of 4.7% YOY (in line with consensus), driven by Hearing Care (we forecast 4.9%) and Diagnostics (we forecast 8.4%), while Hearing Aids faces a tough YOY comparable (we forecast 3.6%). We expect 2024 to be back-end loaded and driven by Oticon Intent. We expect maintained 2024 guidance of 4–8% organic growth, c1% M&A growth, c-1% FX, and EBIT of DKK4.6bn–5.0bn. We reiterate our BUY and DKK400 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK400.00) - Improved long-term outlook

At its CMD, Demant updated its long-term outlook. It now targets 8–10% LCY growth (7–10%) including 6–8%-points organic growth and c2%-points M&A growth, and still sees incremental EBIT margin expansion. It expects the hearing-aid market to grow 4–6% p.a. in value (2–5%), as ASP is now guided fairly flat. We are positive on the Sirius-based Oticon Intent launch. We reiterate our BUY, and have raised our target price to DKK400 (375).

Oliver Metzger
  • Oliver Metzger

Demant A/S : Strong performance to continue

>Strong performance to continue - Demant’s Q4 results showed, with an organic growth of 10%, a continuation of the strong performance of previous quarters. On the back of the announced launch of the new hearing aid platform Oticon Intega, we expect that the market share gains in the hearing aid segment will continue also in 2024. Our organic growth forecast for 2024 stands at 7.4% (guidance 4-8%) for the company driven by an expected 8.0% for the hearing aid wholesale...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch